Spectral AI Inc. (Class A) (MDAI) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Spectral AI Inc. (Class A) (NASDAQ: MDAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.57 (+0.64% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MDAI ranks #1011 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MDAI carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 45.4%, and ROIC of -35.0%. By comparison, DXR (Daxor Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $52.1M) and SRTS (Sensus Healthcare Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -31.3%, cap $45.6M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).
Per MDAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833498), Spectral AI Inc. (Class A) generated $19.6M in revenue (-33.6% YoY), -$7.6M in net income, and -$9.9M in free cash flow against $21.4M in total assets and $5.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±8.9% realized swing band)
FRED Regime × Technicals: 22% of 52W Range • RSI-14 at 45.6 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While MDAI currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.59) and Max Pain ($1.65) forces dealer call-delta covering toward $3.12.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Spectral AI Inc. (Class A) (MDAI) advanced +0.64% to $1.57, trading at 22% of its 52-week range ($1.18 – $2.97). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
DALLAS, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment d
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -33.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDAI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDAI. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Spectral AI Inc. (Class A) (MDAI) ranks #1011 by composite RQD confidence (21/100, grade E) and #750 by equity capitalization ($50.5M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. SNWV currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with MDAI at 21/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MDAI
ACTIVE
Spectral AI Inc. (Class A) | E | 21/100 | — | 45.4% | -35.0% | +0.64% | $50.5M | Benchmark Subject |
| DXR Daxor Corporation | D+ | 52/100 | — | — | — | -0.56% | $52.1M | /dxr-vs-mdai → |
| SRTS Sensus Healthcare Inc. | D | 46/100 | — | 43.2% | -31.3% | -1.77% | $45.6M | /srts-vs-mdai → |
| SNWV SANUWAVE Health Inc. | D+ | 53/100 | 3.8x | 77.1% | 67.3% | 0.00% | $45.3M | /snwv-vs-mdai → |
| TELA TELA Bio Inc. | D- | 36/100 | — | 67.7% | -35.0% | -5.74% | $41.5M | /tela-vs-mdai → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Spectral AI Inc. (Class A) (MDAI) reported GAAP revenue of $19.6M (-33.6% vs. FY2024 revenue of $29.6M , and +8.8% cumulative change since FY2023) , GAAP net income of -$7.6M, operating cash flow of -$9.9M, and free cash flow of -$9.9M (-7.8% YoY). On the balance sheet, MDAI closed FY2025 with $21.4M in total assets against $5.5M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $19.6M | -$7.6M | -$9.9M | -$9.9M | $21.4M | $5.5M |
| FY2024 (FY) | 2024-12-31 | $29.6M | -$15.2M | -$9.2M | -$9.2M | $12.1M | — |
| FY2023 (FY) | 2023-12-31 | $18.1M | -$20.9M | -$13.2M | -$13.2M | — | — |
As of 2026-11-01, Spectral AI Inc. (Class A) (NASDAQ: MDAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.57 (+0.64% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MDAI ranks #1011 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), MDAI carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 45.4%, and ROIC of -35.0%. By comparison, DXR (Daxor Corporation) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $52.1M) and SRTS (Sensus Healthcare Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC -31.3%, cap $45.6M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).
Per MDAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833498), Spectral AI Inc. (Class A) generated $19.6M in revenue (-33.6% YoY), -$7.6M in net income, and -$9.9M in free cash flow against $21.4M in total assets and $5.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
MDAI last traded at $1.57 (+0.64% on volume of 67,903 shares), positioning the stock -1.26% below its 50-day simple moving average ($1.59) and -7.65% below its 200-day simple moving average ($1.70). Across its 52-week range of $1.18 to $2.97, MDAI sits at the 21.8% percentile with a 14-day RSI of 45.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($1.43 to $1.71).
Why MDAI Stock advanced +0.64% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).